CN111551741B - Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis - Google Patents
Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis Download PDFInfo
- Publication number
- CN111551741B CN111551741B CN202010371675.2A CN202010371675A CN111551741B CN 111551741 B CN111551741 B CN 111551741B CN 202010371675 A CN202010371675 A CN 202010371675A CN 111551741 B CN111551741 B CN 111551741B
- Authority
- CN
- China
- Prior art keywords
- ala
- gly
- tuberculosis
- leu
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides application of mycobacterium tuberculosis proteins in preparing products for diagnosing tuberculosis latent infection patients. The method provided by the invention can be used for simultaneously detecting the serum antibody response levels of three different mycobacterium tuberculosis proteins, so that tuberculosis latent infection patients and active tuberculosis patients can be better identified and diagnosed, the sensitivity is higher, and the specificity is better.
Description
The present application is a divisional application of the invention patent application with the application number 2016112595642, the application date of which is 2016, 12 and 30.
Technical Field
The invention relates to the field of biological medicine, in particular to application of mycobacterium tuberculosis proteins in preparation of products for diagnosing tuberculosis latent infection and/or active tuberculosis.
Background
After the human body is infected with the mycobacterium tuberculosis, about 10% of people develop active tuberculosis, but 90% of people do not develop active tuberculosis, but the in-vivo tuberculosis is not completely cleared, but is hidden in the human body, which is called tuberculosis hidden infection, the people do not have any clinical symptoms, most of people do not develop the active tuberculosis in their life, and only 5% -10% of people can cause the occurrence of tuberculosis when the immunity of the human body is reduced. At present, about 1/3 of people in the whole world are infected with tubercle bacillus, and the number of people with latent infection is numerous, so that the people with latent infection are required to be monitored, and medicine treatment is timely given when the infection state changes, so that early detection and early treatment are realized, the worsening of the illness state can be prevented, the treatment time and the side effect caused by medicine treatment can be reduced, and the spreading of tuberculosis can be reduced. Therefore, detection and identification of two states after tuberculosis infection are very important for prevention and treatment of tuberculosis.
There are many methods for detecting tubercle bacillus infection at present, including tubercle bacillus skin test (TST), gamma-interferon release test (IGRA), traditional sputum acid fast bacteria smear, quick culture of mycobacterium, amplification of tuberculosis specific nucleic acid fragment (quantitative and qualitative), etc. TST is skin allergy, and the service time is long, is mainly used for outpatient screening, and although the test is simple and easy to implement, when the tuberculosis infection condition is detected, the same result appears in BCG inoculation, natural infection cannot be identified, the specificity is not strong, and in addition, tuberculosis latent infection and active tuberculosis cannot be identified. The gamma-interferon release assay (IGRA) is mainly used for detecting cellular immune responses, but can exclude the influence of bacillus calmette-guerin inoculation, and can not distinguish latent infection patients from active tuberculosis patients, and can not distinguish patients after treatment from symptomatic infection patients. The traditional sputum acid-fast bacteria smear, mycobacterium rapid culture and the like are mainly used for detecting active tuberculosis patients, have no meaning for judging the latent infection state, and can not find bacteriological evidence for active tuberculosis patients with atypical clinical symptoms. It would therefore be of great value to find a method that would accurately identify latent infection and active tuberculosis.
Based on the difference of host protective immune response caused after tubercle bacillus infection, the search of serum markers for distinguishing latent infection and active tuberculosis has good application prospect. The serological diagnosis of antigen-antibody reaction is focused on the ease and rapidity of sample acquisition, and some specific antigens of mycobacterium tuberculosis are currently used for serological diagnosis of tuberculosis infection, such as secreted protein antigen: antigen 85 complex antigens, i.e., ag85A, ag85B and Ag85C, etc.; lipoprotein antigen: a 16kDa,27kDa,38kDa antigen, etc.; glycolipid antigen: lipoarabinomannan antigen, tubercle bacillus saccharide lipoantigen, etc.; however, in practical use, the antigens have low positive detection rate and cross immunity with other mycobacteria, and have certain value in general investigation, treatment effect monitoring, prognosis judgment and recurrence prompting of high-risk groups, but cannot be used for the definite diagnosis of latent mycobacterium tuberculosis infection at present.
Therefore, it is very important to find a new method and a marker that can accurately diagnose tuberculosis latent infectors and active tuberculosis patients.
Disclosure of Invention
The invention aims to solve the technical problems that in the prior art, products for differential diagnosis of tuberculosis latent infected persons and/or active tuberculosis have low positive detection rate and latent mycobacterium tuberculosis infection cannot be differential diagnosed, and provides application of mycobacterium tuberculosis protein in preparation of products for diagnosis of tuberculosis latent infected persons and/or active tuberculosis.
In order to solve the technical problems, the technical scheme provided by one aspect of the invention is as follows:
use of a product for detecting the level of an anti-Rv 0284 antibody, an anti-Rv 2002 antibody and/or an anti-Rv 2421c antibody in a sample for the preparation of a product for the identification, diagnosis and/or screening of latent tuberculosis infection and/or active tuberculosis.
In the technical scheme of the invention, any product for detecting the level of the anti-Rv 0284 antibody, the anti-Rv 2002 antibody and/or the anti-Rv 2421c antibody in a sample can be used for preparing a product for identifying, diagnosing and/or screening latent tuberculosis infection and/or active tuberculosis.
Preferably, the product of the above detection of the level of anti-Rv 0284 antibody, anti-Rv 2002 antibody and/or anti-Rv 2421c antibody in the sample comprises Rv0284 protein, rv2002 protein and/or Rv2421c protein.
More preferably, the Rv0284 protein is shown in SEQ ID No.1, or one or more amino acid residues in the amino acid sequence shown in SEQ ID No.1 are modified to have the same function as the protein shown in SEQ ID No. 1; the Rv2002 protein is shown in SEQ ID NO.2, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.2 are modified to have the same function as the protein shown in SEQ ID NO. 2; the Rv2421c protein is shown in SEQ ID NO.3, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.3 are modified to have the same function as the protein shown in SEQ ID NO. 3.
The term "engineering" as described above may use any prior art method of engineering proteins, including, but not limited to, substitution and/or addition and/or deletion of amino acid residues, to form derivatives of the original protein.
Preferably, the assay may be any suitable assay known in the art, but preferably, the assay may be an enzyme-linked immunosorbent assay, an agglutination assay, a precipitation assay, an E-garland assay, a small phagocytosis assay, an immunofluorescence assay, a colloidal gold immunochromatography assay, a spot gold immunodiafiltration assay and/or an electrochemiluminescence assay. More preferably, in one embodiment of the invention, the method of detection is an enzyme-linked immunosorbent assay.
Preferably, the sample may be any suitable sample obtained from the subject to be tested. But preferably the sample comprises serum, plasma, saliva, urine, hydrothorax and/or cerebrospinal fluid. More preferably, in one embodiment of the invention, the sample is serum.
Another aspect of the present invention is to provide a marker composition for identifying, diagnosing and/or screening for latent tuberculosis infection and/or active tuberculosis, the marker composition consisting of an anti-Rv 0284 antibody, an anti-Rv 2002 antibody and/or an anti-Rv 2421c antibody;
wherein, the Rv0284 is shown in SEQ ID NO.1, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.1 are modified to have the same function as the protein shown in SEQ ID NO. 1; the Rv2002 is shown in SEQ ID NO.2, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.2 are modified to have the same function as the protein shown in SEQ ID NO. 2; the Rv2421c is shown in SEQ ID NO.3, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.3 are modified to have the same function as the protein shown in SEQ ID NO. 3.
In another aspect, the invention provides the use of a marker composition as described above for the preparation of a product for the identification, diagnosis and/or screening of latent tuberculosis infection and/or active tuberculosis.
In another aspect of the invention there is provided a kit for the identification, diagnosis and/or screening of latent tuberculosis infection and/or active tuberculosis, said kit comprising an Rv0284 protein, an Rv2002 protein and/or an Rv2421c protein.
Preferably, the Rv0284 protein is shown in SEQ ID NO.1, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.1 are modified to have the same function as the protein shown in SEQ ID NO. 1; the Rv2002 protein is shown in SEQ ID NO.2, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.2 are modified to have the same function as the protein shown in SEQ ID NO. 2; the Rv2421c protein is shown in SEQ ID NO.3, or one or more amino acid residues in the amino acid sequence shown in SEQ ID NO.3 are modified to have the same function as the protein shown in SEQ ID NO. 3.
The Rv0284 protein, rv2002 protein and/or Rv2421c protein contained in the above kit may be in any form, including but not limited to direct protein samples, and forms of immobilizing proteins on a carrier such as a detection chip.
In addition to the Rv0284 protein, the Rv2002 protein and/or the Rv2421c protein, the kit includes at least kit instructions.
Criteria for the results are described in the specification: and (3) using three proteins for combined detection, if at least 2 antibodies in the anti-Rv 0284 antibody, the anti-Rv 2002 antibody and/or the anti-Rv 2421c antibody are positive in the detection result of the sample to be detected, judging that the sample to be detected is positive in active tuberculosis, otherwise, judging that the sample to be detected is latent tuberculosis infection.
In another aspect, the invention provides the use of a kit as described above for the preparation of a product for the identification, diagnosis and/or screening of latent tuberculosis infection and/or active tuberculosis.
The beneficial effects of the invention are as follows:
the invention can detect the response level of three different mycobacterium tuberculosis protein serum antibodies at the same time, thereby being capable of better distinguishing and diagnosing tuberculosis latent infection patients and active tuberculosis patients, and having higher sensitivity and better specificity.
Drawings
FIG. 1 is a statistical chart showing ELISA detection of expression levels of anti-Rv 0284 antibody, anti-Rv 2002 antibody and anti-Rv 2421c antibody in serum of tuberculosis latent infected person (n=93) and active tuberculosis patient (n=92);
FIG. 2 is a ROC graph of antibodies corresponding to the combined detection of three antigens;
DESCRIPTION OF THE SEQUENCES
SEQ ID NO.1 is the amino acid sequence of an Rv0284 protein in the examples of the present invention;
SEQ ID NO.2 is the amino acid sequence of the Rv2002 protein in the embodiment of the invention;
SEQ ID NO.3 shows the amino acid sequence of the Rv2421c protein in the examples of the present invention.
Detailed Description
The invention discloses application of a product for detecting the level of an anti-Rv 0284 antibody, an anti-Rv 2002 antibody and/or an anti-Rv 2421c antibody in a sample in preparation of a product for identifying, diagnosing and/or screening latent tuberculosis infection and/or active tuberculosis. Those skilled in the art can, with the benefit of this disclosure, suitably modify the process parameters to achieve this. It is to be particularly pointed out that all similar substitutes and modifications apparent to those skilled in the art are deemed to be included in the invention and that the relevant person can make modifications and appropriate alterations and combinations of what is described herein to make and use the technology without departing from the spirit and scope of the invention.
In the present invention, unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by one of ordinary skill in the art.
In order to enable those skilled in the art to better understand the technical solution of the present invention, the present invention will be further described in detail with reference to specific embodiments.
Example 1: sample collection and processing
The sample detected by the invention is serum, the collection method is that blood of a subject is collected on an empty stomach, a common biochemical test tube without anticoagulant is used, the sample is stood at room temperature and naturally solidified, and is centrifuged for 10 minutes at a speed of 3000 rpm Zhong Changwen, the serum is collected and split-packed in a freezing tube, and the freezing tube is placed in a low-temperature refrigerator at-80 ℃ for preservation and is used for experiments.
The samples used in the present invention are divided into two groups: a group of latent infections and active tuberculosis patients; the latent infection group refers to a patient without clinical complaints, and the TST experiment and the T-SPOT experiment are positive and the chest X-ray film is negative; the active tuberculosis patient group refers to the tuberculosis patients which are positive through smear or culture and are not or just beginning systematic chemical drug treatment; both groups were excluded from diabetes, HIV infection and other autoimmune diseases.
The latent infection group specimen used in the invention is from epidemiological investigation projects of epidemiology research laboratory of Beijing tuberculosis chest tumor research institute, the active tuberculosis patient group specimen is from inpatients in each disease area of Beijing thoracic hospital tuberculosis affiliated to the university of the capital medical science, the subject is approved by ethics committee of Beijing thoracic hospital scientific research affiliated to the university of the capital medical science, and all the research subjects are informed consent.
Example 2: detection of samples using ELISA experiments
1. Various buffers, dilutions, reaction solutions and termination solutions required to establish ELSIA experiments:
(1) Coating buffer (pH 9.6,0.05mol/L carbonate buffer):
Na 2 CO 3 1.59g，NaHCO 3 2.93g of double distilled water is added to 1000ml, and the pH is adjusted to 9.6;
(2) PBS solution at pH 7.4:
NaCl 8.0g，KCl 0.2g，KH 2 PO 4 0.2g，Na 2 HPO 4 ·12H 2 O 2.9g，
adding double distilled water to 1000ml, and regulating pH to 7.4;
(3) PBST wash at ph 7.4:
tween-20 is added into 1000ml of PBS solution for 0.5ml, and the pH is adjusted to 7.4;
(4) Blocking solution (PBS solution ph7.4 containing skimmed milk powder):
5g of skimmed milk powder was added to 100ml of PBS solution;
(5) Substrate buffer: 0.2M NaH 2 PO 4 (28.4g/L)25.7ml，
0.1M citric acid (19.2 g/L) 24.3ml, and distilled water 50ml.
(6) TMB (tetramethylbenzidine) use solution TMB (10 mg/5ml absolute ethanol) 0.5ml substrate
10ml of buffer (pH 5.5) 0.75% H 2 O 2 32μl；
(7) Termination liquid (2M H) 2 SO 4 )：21.32ml H 2 SO 4 ，178.68ml H 2 O。
(8) And (2) secondary antibody: horseradish peroxidase (HRP) -labeled goat anti-human IgG;
(9) 96-well elisa plate; nunc Incorporated (Thermomo, gebenhagen, denmark)
2. The detection step comprises:
(1) Coating: the Rv0284, rv2002 and Rv2421c antigens were dissolved in coating buffer (5 ug/ml) respectively; 100 ul/well was added to the 96-well ELISA plate at 4deg.C overnight;
(2) Washing the plate: PBST washing solution 300 ul/hole for 3min, washing 3 times;
(3) Closing: blocking the solution, 300 ul/hole, and incubating for 1h at room temperature;
(4) Washing the plate: 300 ul/hole of washing liquid, 3min, 3 times of washing;
(5) Adding serum: the serum to be tested is diluted according to the ratio of 1:400, 100 ul/hole is incubated for 1h at room temperature;
(6) Washing the plate: 300 ul/hole of washing liquid, 3min, 5 times of washing;
(7) Adding enzyme-labeled secondary antibodies: 100 ul/well of freshly diluted enzyme-labeled antibody (1:30000), incubated for 1h at room temperature;
(8) Washing the plate: 300 ul/hole of washing liquid, 3min, 5 times of washing;
(9) Color development: freshly prepared TMB color development solution, 100 ul/hole, incubate at room temperature in the dark for 5-10min;
(10) And (3) terminating: termination liquid 2M H 2 SO 4 50 ul/well;
(11) And (3) measuring: the microplate reader was adjusted to 450nm and the OD of each well was measured after zeroing the first blank PBS control well.
3. Result analysis and decision criteria:
drawing a ROC curve by using SPSS22.0 software, obtaining the specificities and sensitivities corresponding to different critical points according to coordinate values, and then calculating about dengue indexes (about dengue indexes = specificities + sensitivities-1), so as to obtain the critical point OD values of three antigens, namely, rv0248 is 0.3475, rv2002 is 0.3048 and Rv2421c is 0.4173;
the results are shown in figure 1, and the results show that all three proteins have the effect of distinguishing latent tuberculosis infection from active tuberculosis.
Determination criteria:
and (3) using three proteins for combined detection, if at least 2 antibodies in the anti-Rv 0284 antibody, the anti-Rv 2002 antibody and/or the anti-Rv 2421c antibody are positive in the detection result of the sample to be detected, judging that the sample to be detected is positive in active tuberculosis, otherwise, judging that the sample to be detected is latent tuberculosis infection.
Example 3: specificity and sensitivity of methods for differential diagnosis of active tuberculosis patients and latent infectors using ELISA
92 parts of patient serum with clinical diagnosis of active tuberculosis and 93 parts of serum of latent infectious agents; the test was carried out by ELISA method in examples 1 and 2, and whether the test person was positive for active tuberculosis was judged by the judgment standard in example 2, and the result was shown in FIG. 2, and the analysis specificity was 83.87% and the sensitivity was 79.35%. In FIG. 2, the abscissa 1-specificity represents the false positive rate, and the ordinate sensitivity represents the true positive rate.
The results prove that the invention detects the serum antibody response level of three different mycobacterium tuberculosis proteins, can better diagnose tuberculosis latent infection patients and active tuberculosis patients in a differential mode, and has higher sensitivity and better specificity.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Sequence listing
<110> Beijing chest Hospital affiliated with university of capital medical science
<120> use of Mycobacterium tuberculosis proteins for the preparation of a product for the diagnosis of tuberculosis latent infected persons and/or active tuberculosis
<130> None
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 645
<212> PRT
<213> Bacteria
<400> 1
Met Val Glu Val Glu Arg His Ser Tyr Asp Val Val Val Ile Gly Ala
1 5 10 15
Gly Gly Ala Gly Leu Arg Ala Val Ile Glu Ala Arg Glu Arg Gly Leu
20 25 30
Lys Val Ala Val Val Cys Lys Ser Leu Phe Gly Lys Ala His Thr Val
35 40 45
Met Ala Glu Gly Gly Cys Ala Ala Ala Met Gly Asn Ala Asn Pro Lys
50 55 60
Asp Asn Trp Lys Thr His Phe Gly Asp Thr Met Arg Gly Gly Lys Phe
65 70 75 80
Leu Asn Asn Trp Arg Met Ala Glu Leu His Ala Lys Glu Ala Pro Asp
85 90 95
Arg Val Trp Glu Leu Glu Thr Tyr Gly Ala Leu Phe Asp Arg Thr Asp
100 105 110
Asp Gly Arg Ile Ser Gln Arg Asn Phe Gly Gly His Thr Tyr Pro Arg
115 120 125
Leu Ala His Val Gly Asp Arg Thr Gly Leu Glu Leu Ile Arg Thr Leu
130 135 140
Gln Gln Lys Val Val Ser Leu Gln Gln Glu Asp His Ala Glu Leu Gly
145 150 155 160
Asp Tyr Glu Ala Arg Ile Lys Val Phe Ala Glu Cys Thr Ile Thr Glu
165 170 175
Leu Leu Lys Asp Gln Gly Ala Ile Ala Gly Ala Phe Gly Tyr Trp Arg
180 185 190
Glu Ser Gly Arg Phe Ile Val Phe Glu Ala Pro Ala Val Val Leu Ala
195 200 205
Thr Gly Gly Ile Gly Lys Ser Phe Lys Val Thr Ser Asn Ser Trp Glu
210 215 220
Tyr Thr Gly Asp Gly His Ala Leu Ala Leu Arg Ala Gly Ala Thr Leu
225 230 235 240
Asn Met Glu Phe Val Gln Phe His Pro Thr Gly Met Val Trp Pro Pro
245 250 255
Ser Val Lys Gly Ile Leu Val Thr Glu Gly Val Arg Gly Asp Gly Gly
260 265 270
Val Leu Lys Asn Ser Glu Asn Ser Arg Phe Met Phe Asp Tyr Ile Pro
275 280 285
Pro Val Phe Lys Gly Gln Tyr Ala Glu Thr Glu Glu Glu Ala Asp Gln
290 295 300
Trp Leu Lys Asp Asn Asp Ser Ala Arg Arg Thr Pro Asp Leu Leu Pro
305 310 315 320
Arg Asp Glu Val Ala Arg Ala Ile Asn Ser Glu Val Lys Ala Gly Arg
325 330 335
Gly Thr Pro His Gly Gly Val Tyr Leu Asp Ile Ala Ser Arg Leu Thr
340 345 350
Pro Ala Glu Ile Lys Arg Arg Leu Pro Ser Met Tyr His Gln Phe Lys
355 360 365
Glu Leu Ala Glu Val Asp Ile Thr Thr Gln Ala Met Glu Val Gly Pro
370 375 380
Thr Cys His Tyr Val Met Gly Gly Val Glu Val Asp Ala Asp Thr Gly
385 390 395 400
Ala Ala Thr Val Pro Gly Leu Phe Ala Ala Gly Glu Cys Ala Gly Gly
405 410 415
Met His Gly Ser Asn Arg Leu Gly Gly Asn Ser Leu Ser Asp Leu Leu
420 425 430
Val Phe Gly Arg Arg Ala Gly Leu Gly Ala Ala Asp Tyr Val Arg Ala
435 440 445
Leu Ser Ser Arg Pro Ala Val Ser Ala Glu Ala Ile Asp Ala Ala Ala
450 455 460
Gln Gln Ala Leu Ser Pro Phe Glu Gly Pro Lys Asp Gly Ser Ala Pro
465 470 475 480
Glu Asn Pro Tyr Ala Leu His Met Asp Leu Gln Tyr Val Met Asn Asp
485 490 495
Leu Val Gly Ile Ile Arg Asn Ala Asp Glu Ile Ser Arg Ala Leu Thr
500 505 510
Leu Leu Ala Glu Leu Trp Ser Arg Tyr His Asn Val Leu Val Glu Gly
515 520 525
His Arg Gln Tyr Asn Pro Gly Trp Asn Leu Ser Ile Asp Leu Arg Asn
530 535 540
Met Leu Leu Val Ser Glu Cys Val Ala Arg Ala Ala Leu Gln Arg Thr
545 550 555 560
Glu Ser Arg Gly Gly His Thr Arg Asp Asp His Pro Gly Met Asp Pro
565 570 575
Asn Trp Arg Arg Ile Leu Leu Val Cys Arg Ala Thr Glu Thr Met Gly
580 585 590
Thr Gly Gly Ser Gly Ser Gly Asp Ser Asn Cys His Ile Asn Val Thr
595 600 605
Gln Gln Leu Gln Thr Pro Met Arg Pro Asp Leu Leu Glu Leu Phe Glu
610 615 620
Ile Ser Glu Leu Glu Lys Tyr Tyr Thr Asp Glu Glu Leu Ala Glu His
625 630 635 640
Pro Gly Arg Arg Gly
645
<210> 2
<211> 260
<212> PRT
<213> Bacteria
<400> 2
Met Ser Gly Arg Leu Ile Gly Lys Val Ala Leu Val Ser Gly Gly Ala
1 5 10 15
Arg Gly Met Gly Ala Ser His Val Arg Ala Met Val Ala Glu Gly Ala
20 25 30
Lys Val Val Phe Gly Asp Ile Leu Asp Glu Glu Gly Lys Ala Val Ala
35 40 45
Ala Glu Leu Ala Asp Ala Ala Arg Tyr Val His Leu Asp Val Thr Gln
50 55 60
Pro Ala Gln Trp Thr Ala Ala Val Asp Thr Ala Val Thr Ala Phe Gly
65 70 75 80
Gly Leu His Val Leu Val Asn Asn Ala Gly Ile Leu Asn Ile Gly Thr
85 90 95
Ile Glu Asp Tyr Ala Leu Thr Glu Trp Gln Arg Ile Leu Asp Val Asn
100 105 110
Leu Thr Gly Val Phe Leu Gly Ile Arg Ala Val Val Lys Pro Met Lys
115 120 125
Glu Ala Gly Arg Gly Ser Ile Ile Asn Ile Ser Ser Ile Glu Gly Leu
130 135 140
Ala Gly Thr Val Ala Cys His Gly Tyr Thr Ala Thr Lys Phe Ala Val
145 150 155 160
Arg Gly Leu Thr Lys Ser Thr Ala Leu Glu Leu Gly Pro Ser Gly Ile
165 170 175
Arg Val Asn Ser Ile His Pro Gly Leu Val Lys Thr Pro Met Thr Asp
180 185 190
Trp Val Pro Glu Asp Ile Phe Gln Thr Ala Leu Gly Arg Ala Ala Glu
195 200 205
Pro Val Glu Val Ser Asn Leu Val Val Tyr Leu Ala Ser Asp Glu Ser
210 215 220
Ser Tyr Ser Thr Gly Ala Glu Phe Val Val Asp Gly Gly Thr Val Ala
225 230 235 240
Gly Leu Ala His Asn Asp Phe Gly Ala Val Glu Val Ser Ser Gln Pro
245 250 255
Glu Trp Val Thr
260
<210> 3
<211> 211
<212> PRT
<213> Bacteria
<400> 3
Met Gly Gly Thr Phe Asp Pro Ile His Tyr Gly His Leu Val Ala Ala
1 5 10 15
Ser Glu Val Ala Asp Leu Phe Asp Leu Asp Glu Val Val Phe Val Pro
20 25 30
Ser Gly Gln Pro Trp Gln Lys Gly Arg Gln Val Ser Ala Ala Glu His
35 40 45
Arg Tyr Leu Met Thr Val Ile Ala Thr Ala Ser Asn Pro Arg Phe Ser
50 55 60
Val Ser Arg Val Asp Ile Asp Arg Gly Gly Pro Thr Tyr Thr Lys Asp
65 70 75 80
Thr Leu Ala Asp Leu His Ala Leu His Pro Asp Ser Glu Leu Tyr Phe
85 90 95
Thr Thr Gly Ala Asp Ala Leu Ala Ser Ile Met Ser Trp Gln Gly Trp
100 105 110
Glu Glu Leu Phe Glu Leu Ala Arg Phe Val Gly Val Ser Arg Pro Gly
115 120 125
Tyr Glu Leu Arg Asn Glu His Ile Thr Ser Leu Leu Gly Gln Leu Ala
130 135 140
Lys Asp Ala Leu Thr Leu Val Glu Ile Pro Ala Leu Ala Ile Ser Ser
145 150 155 160
Thr Asp Cys Arg Gln Arg Ala Glu Gln Ser Arg Pro Leu Trp Tyr Leu
165 170 175
Met Pro Asp Gly Val Val Gln Tyr Val Ser Lys Cys Arg Leu Tyr Cys
180 185 190
Gly Ala Cys Asp Ala Gly Ala Arg Ser Thr Thr Ser Leu Ala Ala Gly
195 200 205
Asn Gly Leu
210
Claims (4)
1. Use of a product for detecting levels of an anti-Rv 0284 antibody, an anti-Rv 2002 antibody and an anti-Rv 2421c antibody in a sample in the preparation of a product for the identification, diagnosis and/or screening of tuberculosis latent infection;
the sample is serum.
2. A use according to claim 1, wherein the products for detecting levels of anti-Rv 0284, anti-Rv 2002 and anti-Rv 2421c antibodies in a sample comprise Rv0284, rv2002 and Rv2421c proteins.
3. The use according to claim 2, wherein the Rv0284 protein is shown in SEQ ID No. 1; the Rv2002 protein is shown as SEQ ID NO. 2; the Rv2421c protein is shown in SEQ ID NO. 3.
4. The use according to any one of claims 1 to 3, wherein the method of detection comprises an enzyme-linked immunosorbent assay, an agglutination assay, a precipitation assay, an E-garland assay, a small phagocytosis assay, an immunofluorescence assay, a colloidal gold immunochromatography assay, a spot gold immunodiafiltration assay and/or an electrochemiluminescence assay.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010371675.2A CN111551741B (en) | 2016-12-30 | 2016-12-30 | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611259564.2A CN108267589B (en) | 2016-12-30 | 2016-12-30 | Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis |
| CN202010371675.2A CN111551741B (en) | 2016-12-30 | 2016-12-30 | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611259564.2A Division CN108267589B (en) | 2016-12-30 | 2016-12-30 | Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111551741A CN111551741A (en) | 2020-08-18 |
| CN111551741B true CN111551741B (en) | 2023-06-16 |
Family
ID=62754940
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010371686.0A Active CN111521819B (en) | 2016-12-30 | 2016-12-30 | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis |
| CN201611259564.2A Active CN108267589B (en) | 2016-12-30 | 2016-12-30 | Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis |
| CN202010371675.2A Active CN111551741B (en) | 2016-12-30 | 2016-12-30 | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010371686.0A Active CN111521819B (en) | 2016-12-30 | 2016-12-30 | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis |
| CN201611259564.2A Active CN108267589B (en) | 2016-12-30 | 2016-12-30 | Application of mycobacterium tuberculosis protein in preparing product for diagnosing latent tuberculosis infected person and/or active tuberculosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN111521819B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111157745A (en) * | 2020-01-17 | 2020-05-15 | 上海交通大学 | Application of human SNRPA protein in lung cancer recurrence or metastasis monitoring |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105388297A (en) * | 2013-11-25 | 2016-03-09 | 广东体必康生物科技有限公司 | Application of mycobacterium tuberculosis protein Rv1984c in preparing products for diagnosing latent phthisis infection |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2405247A1 (en) * | 2000-04-19 | 2001-10-25 | Statens Serum Institut | Tuberculosis antigens and methods of use thereof |
| EP1354207A2 (en) * | 2000-12-29 | 2003-10-22 | Triad Therapeutics, Inc. | Prediction of functional and structural properties of polypeptides |
| WO2006029248A2 (en) * | 2004-09-04 | 2006-03-16 | Haper Laboratories Llc | Hollow fiber technique for in vivo study of cell populations |
| EA013016B1 (en) * | 2005-03-31 | 2010-02-26 | Лейден Юниверсити Медикал Сентер | Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis |
| WO2007131291A1 (en) * | 2006-05-16 | 2007-11-22 | Proteome Systems Limited | Methods of diagnosis and treatment of m. tuberculosis infection and reagents therefore |
| WO2008134806A1 (en) * | 2007-05-04 | 2008-11-13 | The University Of Sydney | Mycobacterium antigens |
| EP2197908A2 (en) * | 2007-09-27 | 2010-06-23 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| US7670609B2 (en) * | 2007-11-27 | 2010-03-02 | Aeras Global Tb Vaccine Foundation | Recombinant BCG tuberculosis vaccine designed to elicit immune responses to Mycobacterium tuberculosis in all physiological stages of infection and disease |
| CN101294964B (en) * | 2007-11-27 | 2012-06-27 | 复旦大学附属华山医院 | Reagent and method for detecting active tuberculosis and tuberculosis dormant infection |
| US8361482B2 (en) * | 2007-11-27 | 2013-01-29 | Aeras Global Tb Vaccine Foundation | Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease |
| CN101493454A (en) * | 2008-01-21 | 2009-07-29 | 范雄林 | Tuberculosis antigen specific whole blood IFN-gamma diagnosis kit, method for producing the same and method for using same |
| GB0906215D0 (en) * | 2009-04-09 | 2009-05-20 | Lalvani Ajit | Diagnostic test |
| CN102590502B (en) * | 2012-01-11 | 2014-07-02 | 北京市结核病胸部肿瘤研究所 | Kit for auxiliary diagnosis of tuberculosis patients |
| CN103698530B (en) * | 2013-11-25 | 2015-08-19 | 广东体必康生物科技有限公司 | The purposes of Mycobacterium tuberculosis albumen in the phthisical product of preparation diagnostic activities |
| WO2016046734A2 (en) * | 2014-09-22 | 2016-03-31 | University Of The Western Cape | Compounds and compositions for treatment of tuberculosis |
| CN105588944B (en) * | 2016-02-25 | 2017-05-24 | 首都医科大学附属北京胸科医院 | Application of AGP1, SERPINA3 and CDH1 content detection system in screening active tuberculosis patients |
-
2016
- 2016-12-30 CN CN202010371686.0A patent/CN111521819B/en active Active
- 2016-12-30 CN CN201611259564.2A patent/CN108267589B/en active Active
- 2016-12-30 CN CN202010371675.2A patent/CN111551741B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105388297A (en) * | 2013-11-25 | 2016-03-09 | 广东体必康生物科技有限公司 | Application of mycobacterium tuberculosis protein Rv1984c in preparing products for diagnosing latent phthisis infection |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111521819B (en) | 2023-06-20 |
| CN111551741A (en) | 2020-08-18 |
| CN111521819A (en) | 2020-08-11 |
| CN108267589A (en) | 2018-07-10 |
| CN108267589B (en) | 2020-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haque et al. | Diagnosis of amebiasis in Bangladesh | |
| Chan et al. | Diagnosis of tuberculosis by a visually detectable immunoassay for lipoarabinomannan | |
| JP3969722B2 (en) | Candida detection | |
| Feng et al. | Enhanced serodiagnostic utility of novel Mycobacterium tuberculosis polyproteins | |
| Lei et al. | Different methods of COVID-19 detection | |
| KR101775851B1 (en) | Method and kit for diagnosis of tuberculosis based on Mycobacterium tuberculosis antigen-specific antibody reaction | |
| CN111551741B (en) | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis | |
| Ng et al. | Serodiagnosis of pericardial tuberculosis | |
| JP4419020B2 (en) | Method for detecting Mycobacterium tuberculosis antigen in body fluid | |
| Cooper et al. | ELISA and immuno–polymerase chain reaction assays for the sensitive detection of melioidosis | |
| McConkey S et al. | Evaluation of a rapid-format antibody test and the tuberculin skin test for diagnosis of tuberculosis in two contrasting endemic settings | |
| Harinath et al. | A cocktail of affinity-purified antibodies reactive with diagnostically useful mycobacterial antigens ES-31, ES-43, and EST-6 for detecting the presence of Mycobacterium tuberculosis | |
| CN111551742B (en) | Use of mycobacterium tuberculosis proteins in the preparation of a product for diagnosing tuberculosis latency infected persons and/or active tuberculosis | |
| KR102132964B1 (en) | Method for Diagnosing Scrub Typhus Using Exosome derived from Orientia tsutsugamushi | |
| CN105388291B (en) | Gamma delta T cell surface activation molecule and kit for quickly diagnosing active tuberculosis | |
| Tabasi et al. | Development of an indirect ELISA based on whole cell Brucella abortus S99 lysates for detection of IgM anti-Brucella antibodies in human serum | |
| Sarkari et al. | A comparative study of antigen and antibody detection in visceral leishmaniasis using serum and urine-based ELISA | |
| Cheng et al. | Amoebiasis among institutionalized psychiatric patients in Taiwan | |
| KR20160139888A (en) | Method and kit for diagnosis of tuberculosis based on Mycobacterium tuberculosis antigen-specific antibody reaction | |
| CN106814194B (en) | A kind of kit for distinguishing activity and latent tuberculosis infects | |
| CN107202894B (en) | Purposes of the Rv1078 albumen in diagnosis latency/active tuberculosis | |
| Nazri et al. | Detection of Plasmodium knowlesi in whole blood samples with sandwich enzyme-linked immunosorbent assay (ELISA) using rhoptry-associated protein 1 specific polyclonal antibodies | |
| HassanP | Comparative Study of Enzyme Linked Immunosorbant Assay and Agglutination Tests in the Diagnosis of Human Brucellosis in Baghdad | |
| Meshram et al. | Sandwich elisa for tubercular antigen detection in AFB sputum positive tubercular patients in rural based Tertiary Care Hospital | |
| RU2503006C1 (en) | Diagnostic technique for tuberculosis infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |